473 related articles for article (PubMed ID: 9443406)
1. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
2. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
4. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line.
Leonetti C; Biroccio A; Benassi B; Stringaro A; Stoppacciaro A; Semple SC; Zupi G
Cancer Gene Ther; 2001 Jun; 8(6):459-68. PubMed ID: 11498766
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
6. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
7. Enhancement effect of adenovirus-mediated antisense c-myc and caffeine on the cytotoxicity of cisplatin in osteosarcoma cell lines.
Xie XK; Yang DS; Ye ZM; Tao HM
Chemotherapy; 2009; 55(6):433-40. PubMed ID: 19996588
[TBL] [Abstract][Full Text] [Related]
8. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase.
Berg RW; Werner M; Ferguson PJ; Postenka C; Vincent M; Koropatnick DJ; Behrend E
J Pharmacol Exp Ther; 2001 Aug; 298(2):477-84. PubMed ID: 11454908
[TBL] [Abstract][Full Text] [Related]
9. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.
Pastorino F; Mumbengegwi DR; Ribatti D; Ponzoni M; Allen TM
J Control Release; 2008 Feb; 126(1):85-94. PubMed ID: 18166243
[TBL] [Abstract][Full Text] [Related]
10. The effect of p21 antisense oligodeoxynucleotides on the radiosensitivity of nasopharyngeal carcinoma cells with normal p53 function.
Liu XF; Xia YF; Li MZ; Wang HM; He YX; Zheng ML; Yang HL; Huang WL
Cell Biol Int; 2006 Mar; 30(3):283-7. PubMed ID: 16448826
[TBL] [Abstract][Full Text] [Related]
11. Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells.
Wang J; Liu X; Jiang W
Chin Med J (Engl); 2000 Oct; 113(10):957-60. PubMed ID: 11775848
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
13. Recombinant antisense C-myc adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to cisplatin.
Xie XK; Yang DS; Ye ZM; Tao HM
Cancer Invest; 2006 Feb; 24(1):1-8. PubMed ID: 16466985
[TBL] [Abstract][Full Text] [Related]
14. Antisense-mediated melanoma inhibitor of apoptosis protein downregulation sensitizes G361 melanoma cells to cisplatin.
Mousavi-Shafaei P; Ziaee AA; Azizi E; Zangemeister-Wittke U
Anticancer Drugs; 2006 Oct; 17(9):1031-9. PubMed ID: 17001176
[TBL] [Abstract][Full Text] [Related]
15. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
Cucco C; Calabretta B
Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.
Iversen PL; Arora V; Acker AJ; Mason DH; Devi GR
Clin Cancer Res; 2003 Jul; 9(7):2510-9. PubMed ID: 12855625
[TBL] [Abstract][Full Text] [Related]
18. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells.
Ginobbi P; Geiser TA; Ombres D; Citro G
Anticancer Res; 1997; 17(1A):29-35. PubMed ID: 9066627
[TBL] [Abstract][Full Text] [Related]
19. Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression.
Stewart DA; Xu X; Thomas SD; Miller DM
Nucleic Acids Res; 2002 Jun; 30(11):2565-74. PubMed ID: 12034846
[TBL] [Abstract][Full Text] [Related]
20. [The effect of antisense H-ras on growth and metastasis of a high metastatic tumor model of human hepatoma in nude mice LCI-D20].
Liao Y; Tang Z; Sun F
Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):650-3. PubMed ID: 9275544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]